Max Levin
Impact in
- Cancer Research top 10%
- Cancer, Hypoxia, and Metabolism
- Immunology top 10%
- Atherosclerosis and Cardiovascular Diseases
- Immunotherapy and Immune Responses
Papers in
- Immunology 16
- Immunotherapy and Immune Responses 8
- Atherosclerosis and Cardiovascular Diseases 7
-
- Ocular Oncology and Treatments 6
- Co-authors
- Tom BjörnhedenOlov WiklundLillemor Mattsson HulténJan BorénMarcus StåhlmanLars NyOlli LeppänenJens Nielsen
- Journals
- Arteriosclerosis Thrombosis and Vascular Biology (4 papers)PLoS ONE (4 papers)Novartis Foundation symposium (2 papers)Atherosclerosis (2 papers)Journal of Clinical Oncology (2 papers)
- Partner nations
- SwedenUnited StatesGermany
In The Last Decade
Max Levin
53 papers receiving 1.8k citations
Peers
Comparison fields: 5 of 110
- Cancer Research 301
- Immunology 337
- Biochemistry 113
- Molecular Biology 914
- Physiology 335
Countries citing papers authored by Max Levin
This map shows the geographic impact of Max Levin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max Levin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max Levin more than expected).
Fields of papers citing papers by Max Levin
This network shows the impact of papers produced by Max Levin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max Levin. The network helps show where Max Levin may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Max Levin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 1 | |
| 3 | 2024 | 3 | |
| 4 | 2024 | 9 | |
| 5 | 2024 | 4 | |
| 6 | 2022 | 17 | |
| 7 | 2021 | 5 | |
| 8 | 2021 | 120 | |
| 9 | 2019 | 52 | |
| 10 | 2019 | 41 | |
| 11 | 2019 | 6 | |
| 12 | 2017 | 20 | |
| 13 | 2015 | 14 | |
| 14 | 2009 | 5 | |
| 15 | 2009 | 2 | |
| 16 | 2007 | 41 | |
| 17 | 2006 | 13 | |
| 18 | 2006 | 1 | |
| 19 | 2006 | 81 | |
| 20 | 2005 | 29 |
About Max Levin
Max Levin is a scholar working on Immunology, Ophthalmology, Cancer Research, Immunology and Allergy and Oncology, having authored 56 papers that have together received 1.8k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (9 papers), Immunotherapy and Immune Responses (8 papers), Atherosclerosis and Cardiovascular Diseases (7 papers), Ocular Oncology and Treatments (6 papers), Melanoma and MAPK Pathways (5 papers), Cardiovascular Disease and Adiposity (4 papers), Angiogenesis and VEGF in Cancer (4 papers) and Protease and Inhibitor Mechanisms (4 papers). The work is most often cited by research in Cancer Research (301 citations), Immunology (337 citations), Biochemistry (113 citations), Molecular Biology (914 citations) and Physiology (335 citations). Max Levin has collaborated with scholars based in Sweden, United States and Germany. Frequent co-authors include Tom Björnheden, Olov Wiklund, Lillemor Mattsson Hultén, Jan Borén, Marcus Ståhlman, Lars Ny, Olli Leppänen, Jens Nielsen, Francesco Gatto and Angelo Limeta. Their work appears in journals such as Arteriosclerosis Thrombosis and Vascular Biology, PLoS ONE, Novartis Foundation symposium, Atherosclerosis and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.